HCP&Company

HCP&Company does not list any managing partners, principals, or investment committee members on its website or in accessible public records. The firm’s contact email routes to a generic address, reinforcing an intentionally low-profile leadership structure. When names are eventually disclosed, they will be reflected here.

The firm targets buyouts and growth investments in small companies where owner-operators are seeking a transition or institutional partnership. It deploys capital alongside hands-on operational support. Its portfolio spans healthcare services, consumer brands, and education providers, with no evidence of participating in venture-stage or minority-passive deals.

The firm’s structural details are not publicly disclosed. There is no record of a named fund, Limited Partner base, or regulatory filings that describe a traditional blind-pool fund architecture. This silence may indicate direct dealmaking, single-asset vehicles, or a permanently capitalized vehicle — each consistent with its small-deal, low-profile model, but none confirmable.

HCP&Company limits its stated focus to consumer, education, and healthcare. The firm has not signaled interest in technology, industrials, financial services, or other sectors, and its portfolio contains no trace of investments outside those three verticals.

The sale of NYX Cosmetics to L’Oréal in 2014 stands as the firm’s marquee realized investment. HCP&Company backed the accessible professional color cosmetics brand before the strategic acquisition. An earlier exit, Samy Companies to Hoyu Co. Ltd, closed in 2008.